A5073889721- Estrogen and related hormone effects
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Monoclonal and Polyclonal Antibodies Research
- Breast Lesions and Carcinomas
- Lung Cancer Treatments and Mutations
- Glycosylation and Glycoproteins Research
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Cancer-related Molecular Pathways
- BRCA gene mutations in cancer
- Lung Cancer Research Studies
- Global Cancer Incidence and Screening
- PARP inhibition in cancer therapy
- Breast Implant and Reconstruction
- Lung Cancer Diagnosis and Treatment
- Gene expression and cancer classification
- Immunotherapy and Immune Responses
- Growth Hormone and Insulin-like Growth Factors
- Computational Drug Discovery Methods
- Cancer Risks and Factors
- Prostate Cancer Treatment and Research
- Protein Kinase Regulation and GTPase Signaling
University of Nottingham
2016-2025
Royal Derby Hospital
2013-2025
University Hospitals of Derby and Burton NHS Foundation Trust
2020-2024
University of Derby
2024
Nottingham University Hospitals NHS Trust
2007-2023
Queen's Medical Centre
1995-2023
Queen's University
2023
Western General Hospital
2023
Emory University
2011-2020
Nottingham City Hospital
2005-2019
Abstract BACKGROUND. Triple‐negative breast cancer (estrogen receptor‐negative, progesterone and HER2‐negative) is a high risk that lacks the benefit of specific therapy targets these proteins. METHODS. In this study, authors examined large well characterized series invasive carcinoma (n = 1944) with long‐term clinical follow‐up (median, 56 months) by using tissue microarray. The were also stained concurrent immunohistochemical prognostic panels receptor, HER‐2, androgen epidermal growth...
PURPOSE: To compare the efficacy and tolerability of anastrozole (Arimidex; AstraZeneca, Wilmington, DE, Macclesfield, United Kingdom) with that tamoxifen as first-line therapy for advanced breast cancer (ABC) in postmenopausal women. PATIENTS AND METHODS: This randomized, double-blind, multicenter study evaluated 1 mg once daily relative to 20 patients tumors were hormone receptor–positive or unknown receptor status who eligible endocrine therapy. The primary end points time progression...
PURPOSE: To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. PATIENTS AND METHODS: Patients (n = 451) were randomized to receive 250 mg as a once-monthly (one × 5 mL) intramuscular injection or an oral dose 1 this open, parallel-group, multicenter trial. The primary end point was time progression (TTP). Secondary points included objective response (OR)...
Recent studies on gene molecular profiling using cDNA microarray in a relatively small series of breast cancer have identified biologically distinct groups with apparent clinical and prognostic relevance. The validation such new taxonomies should be confirmed larger cases prior to acceptance practice. development tissue (TMA) technology provides methodology for high-throughput concomitant analyses multiple proteins large numbers archival tumour samples. In our study, we used...
We have examined basal and luminal cell cytokeratin expression in 1944 cases of invasive breast carcinoma, using tissue microarray (TMA) technology, to determine the frequency each subtype, their relationships prognostic relevance, if any. Expression was determined by immunocytochemistry staining antibodies cytokeratins (CKs) 7/8, 18 19 markers CK 5/6 14. Additionally, assessment alpha-smooth muscle actin (SMA) oestrogen receptor status (ER) performed. The vast majority showed positivity for...
Purpose The third-generation nonsteroidal aromatase inhibitors (AIs) are increasingly used as adjuvant and first-line advanced therapy for postmenopausal, hormone receptor–positive (HR+) breast cancer. Because many patients subsequently experience progression or relapse, it is important to identify agents with efficacy after AI failure. Materials Methods Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT) a randomized, double-blind, placebo controlled, multicenter phase III trial...
To evaluate the efficacy and tolerability of fulvestrant (Faslodex; AstraZeneca Pharmaceuticals LP, Wilmington, DE), a new estrogen receptor (ER) antagonist that downregulates ER has no agonist effects, versus tamoxifen, an antiestrogen with for treatment advanced breast cancer in postmenopausal women.In this multicenter, double-blind, randomized trial, patients metastatic/locally previously untreated disease were randomly assigned to receive either (250 mg, via intramuscular injection, once...
To compare the clinical activity of pure antiestrogen fulvestrant at 500 mg/mo (double approved dose) with aromatase inhibitor anastrozole as first-line endocrine therapy for advanced hormone receptor-positive breast cancer in postmenopausal women.FIRST (Fulvestrant First-Line Study Comparing Endocrine Treatments) is a phase II, randomized, open-label, multicenter study high-dose (HD) regimen (500 plus mg on day 14 month 1) versus (1 mg/d). The primary efficacy end point was benefit rate...
BackgroundPreoperative and perioperative aromatase inhibitor (POAI) therapy has the potential to improve outcomes in women with operable oestrogen receptor-positive primary breast cancer. It also been suggested that tumour Ki67 values after 2 weeks (Ki672W) of POAI predicts individual patient outcome better than baseline (Ki67B). The POETIC trial aimed test these two hypotheses.MethodsPOETIC was an open-label, multicentre, parallel-group, randomised, phase 3 (done 130 UK hospitals) which...
Purpose To compare overall survival (OS) for fulvestrant 500 mg versus anastrozole as first-line endocrine therapy advanced breast cancer. Patients and Methods The Fulvestrant First-Line Study Comparing Endocrine Treatments (FIRST) was a phase II, randomized, open-label, multicenter trial. Postmenopausal women with estrogen receptor–positive, locally advanced/metastatic cancer who had no previous disease received either (days 0, 14, 28, every 28 days thereafter) or 1 (daily). primary end...
Abstract BACKGROUND Fulvestrant (ICI 182,780) is a new type of estrogen receptor (ER) antagonist that down‐regulates the ER and has no known agonist effects. The authors report prospectively planned combined analysis data from 2 Phase III trials comparing fulvestrant 250 mg monthly ( n = 428) anastrozole 1 daily 423) in postmenopausal women with advanced breast carcinoma (ABC) who previously had progressed after receiving endocrine treatment. METHODS primary endpoint was time to progression...
The epidermal growth factor receptor (EGFR) family plays an important role in breast carcinogenesis. Much interest has been focused recently on its members because of their potential as prognostic indicators cancer and involvement therapy. We have evaluated more than 1500 cases invasive carcinoma immunohistochemically using tissue microarray technology to examine the expression EGFR proteins. found that 20.1 31.8% were positive for c-erbB-2, respectively, 45 45.1% tumours overexpressed...
It is believed that growth factor phosphorylation cascades interact closely with oestrogen receptor (ER) signaling to regulate breast cancer growth, and alterations in these pathways may underlie resistance anti-hormones such as tamoxifen. There an increasing body of experimental evidence implicating the mitogen-activated protein kinase extracellular signal-regulated-kinases ERK1 ERK2 (ERK1/2 MAPK) events. The present study first address relationship between ERK1/2 MAPK (p-MAPK) response...
BackgroundAutoantibodies may be present in a variety of underlying cancers several years before tumours can detected and testing for their presence allow earlier diagnosis. We report the clinical validation an autoantibody panel newly diagnosed patients with lung cancer (LC).Patients methodsThree cohorts LC were identified: group 1 (n = 145), 2 241) 3 269). Patients individually matched by gender, age smoking history to control individual no malignant disease. Serum samples obtained after...